Drugs / Interferon-a2b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01622933 | Jun 2012 → May 2016 | melanoma | Lisa H. Butterfield, Ph.D. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03178123 Comparator | May 2017 → Apr 2022 | mucosal melanoma | Shanghai Junshi Bioscience Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interferon a-2B | “Subjects randomized to receive the IFNa2b boost will receive Interferon-a2b, 20 MU/m2/d (rounded to the nearest 1 million units) administered intravenously for 5 consecutive...” NCT01622933 ↗ |
| Modality | Protein / enzyme biologic | “recombinant interferon a-2B” NCT03178123 ↗ |
| Route | Intravenous | “administered intravenously” NCT01622933 ↗ |